protac brd2/brd4 degrader-1

PROTAC BRD2 BRD4 degrader-1 (compound 15) serves as a potent, selective degrader of BET proteins BRD4 and BRD2, achieving rapid, reversible, and unexpectedly selective elimination of BRD4 and BRD2 compared to BRD3. Its efficacy in suppressing solid tumors manifest with minimal cytotoxic effects. This compound comprises a BET inhibitor, a connecting linker, and thalidomide as the ligand for cereblon (CRBN) cullin 4A[1].

ARV-771 是基于 PROTAC 技术的有效 BET 降解剂，对 BRD2(1)、BRD2(2)、BRD3(1)、BRD3(2)、BRD4 (1) 和 BRD4(2)的 Kd 分别为 34、4.7、8.3、7.6、9.6 和 7.6 nM。

BET-IN-6 是一种有效且高亲和力的BRD2 BRD4抑制剂。BET-IN-6 是靶蛋白 BRD2 4 的配体，可用于合成 PROTAC BRD2 BRD4 degrader-1 。

Thalidomide-NH-C4-NH2 TFA (compound 29c) is a conjugate consisting of an E3 ligase ligand-linker, incorporating the Thalidomide-based cereblon ligand and a linker moiety. This compound, Thalidomide-NH-C4-NH2 TFA, is utilized as a component in PROTAC BRD2 BRD4 degrader-1, which is a highly potent and selective degrader targeting BET proteins BRD4 and BRD2[1].

SJ46421为一种基于(+)-JQ-1的KLHDC2PROTAC蛋白降解剂。该化合物能够有效促进与KLHDC2形成较稳定的三元复合物，具有7.8 nM的IC50值。此外，SJ46421还可促进BRD2、BRD3或BRD4的BD2结构域发生多泛素化。

SJ44236 是一种BET的PROTAC降解剂，能够降解BRD2(DC50= 0.127 nM)、BRD3和BRD4。在细胞 MV4-11 和 HD-MB03 中，SJ44236 的细胞毒性IC50分别是 0.12 nM 和 0.92 nM。该化合物下调c-Myc的表达，同时上调p53。SJ44236 在小鼠体内具有良好的口服生物利用度（45%）。(Pink: ligand for target protein JQ-1 carboxylic acid; Black: linker; Blue: ligand for E3 ligaseCereblonE3ligaseLigand 54)

OARV-771 是一种基于 VHL 的 BET 降解剂 (PROTAC)，具有改善的细胞通透性。OARV-771 显示 Brd4、Brd2 和 Brd3的 DC50分别为 6、1 和 4 nM。